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Adjuvant endocrine therapy improves recurrence and survival rates, but has side effects and is inconvenient. The aim of this
study was to determine the preferences of premenopausal women who had adjuvant endocrine therapy in a randomised trial. In all,
85 (or eighty-five) women completed semistructured interviews 6–30 months after finishing adjuvant endocrine therapy.
Hypothetical scenarios based on known potential survival times (5 or 15 years) and rates (60% or 80% at 5 years) without
adjuvant endocrine therapy were used to determine the smallest gains women judged necessary to make their adjuvant endocrine
therapy worthwhile. Although a third of the women considered gains of 1% in survival rates or 6 months in survival times sufficient to
make their adjuvant endocrine therapy worthwhile, more than half the women required gains of at least 5% in survival rates or 3 years
in survival time as necessary to make adjuvant endocrine therapy worthwhile. Larger benefits were required by women who had
longer treatment, worse side effects, and by those who were treated with goserelin alone. The route of administration (tablet
vs injection) did not affect preferences and some women judged small benefits sufficient to make their adjuvant endocrine
therapy worthwhile, but many women required larger benefits than their counterparts in similar studies of preferences for
adjuvant chemotherapy.
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Adjuvant endocrine therapy reduces recurrence rates and im-
proves overall survival in women with hormone-receptor positive
early breast cancer. The relative effects of these treatments seem to
be independent of nodal status, menopausal status, age, and use of
adjuvant chemotherapy. The absolute benefits for an individual
woman depend on her baseline risk of recurrence. The Oxford
Overviews suggest that 5 years of adjuvant tamoxifen improves
10-year survival rates by 5–11%, and that ovarian ablation
improves 10-year survival rates by 6–13%. (Early Breast Cancer
Trialists’ Collaborative Group, 1998, 2005).
Adjuvant endocrine therapy has side effects that may include a
wide range of menopausal symptoms, infertility, and osteoporosis.
The side effects of endocrine therapy may be less intense than
those of chemotherapy, but they are perhaps more important to
women than clinicians realise (Fellowes et al, 2001). While
adjuvant endocrine therapy is of undoubted benefit to a group
of women with hormone-receptor positive breast cancer, it is
unnecessary for some individuals in the group because their
cancer would not have recurred in any case, and it is ineffective for
others whose cancer would recur just as early with adjuvant
endocrine therapy as without it. The effects of various combina-
tions of ovarian ablation, chemotherapy, tamoxifen, and aromatase
inhibitors in younger women with hormone-receptor positive early
breast cancer are the subject of ongoing international randomised
trials (Dellapasqua et al, 2005).
We aimed to determine the benefits judged necessary to
make adjuvant endocrine therapy worthwhile by women who
participated in a large randomised clinical trial evaluating 2 years
of adjuvant endocrine therapy with tamoxifen, goserelin, or
both in women 50 years or younger with early breast cancers
that expressed hormone receptors (the Under Fifties Trial)
(Dellapasqua et al, 2005). This trial was of a pragmatic design,
allowing a range of local treatments and adjuvant chemotherapy
if required. Measuring the preferences of patients who have had
a treatment gives insights into how they trade-off the treatment’s
benefits and harms. Many women with early breast cancer judge
small benefits sufficient to make adjuvant chemotherapy worth-
while despite its inconvenience and side effects (Duric and
Stockler, 2001; Jansen et al, 2001; Duric et al, 2005). The benefits
of adjuvant endocrine therapy in women with hormone-receptor
positive breast cancer are comparable to those of adjuvant
chemotherapy. Most women who had adjuvant endocrine therapy
as part of routine clinical practice judged modest gains necessary
to make adjuvant endocrine therapy worthwhile (Thewes et al,
2005). How comparable are these benefits to those of premeno-
pausal women who had adjuvant endocrine therapy for early
breast cancer as part of a randomised trial?
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Participants
Women in the Under Fifties trial had invasive, operable early
breast cancer that had already been treated with standard surgery,
with or without adjuvant radiotherapy, and with or without
adjuvant chemotherapy. Eligible consenting women were rando-
mised to one of four arms:
(1) Observation without adjuvant endocrine therapy;
(2) Tamoxifen 20mg daily by mouth for 2 years;
(3) Goserelin 3.6mg monthly by subcutaneous injection for
2 years and;
(4) Both tamoxifen 20mg daily and goserelin 3.6mg monthly for
2 years.
New information about the benefits of tamoxifen for women
under 50 years became available from the Oxford Overviews
during recruitment and investigators were subsequently given the
option of limiting randomisation to two of the arms by prescribing
tamoxifen and then randomising whether goserelin was given.
Most women in the current preferences study were recruited in the
latter years of the trial when tamoxifen was prescribed to most
women with hormone-receptor positive tumours (rather than
randomly allocated).
We approached 120 women in the Under Fifties Trial from
10 UK hospitals who completed their adjuvant endocrine therapy
6–30 months previously (and 30–60 months from trial entry):
88 agreed and 85 (71%) were interviewed. The median time
from trial entry to interview was 36 months. The reasons for
nonparticipation were the following: declined (17), no response
or lost to follow-up (16), agreed but did not attend (3).
Women gave separate, written informed consent for the prefer-
ences study.
Preferences
During a semistructured interview, participants answered a series
of questions about hypothetical clinical scenarios based on those
developed by Simes and Coates (2001) to survey preferences for
adjuvant chemotherapy in early breast cancer. Two different types
of questions were asked: a ‘survival time trade-off’ based on
increasing a given length of survival time; and a ‘survival rate
trade-off’ based on increasing the probability of surviving a given
length of time. Participants identified the smallest improvement in
survival time or survival rate they judged necessary to make
adjuvant endocrine therapy worthwhile. Women who had endo-
crine therapy were asked to base their judgements on their
own experience. Women who did not have adjuvant endocrine
therapy (seven out of 85, 8%) were given a list of the common
side effects of adjuvant endocrine therapy. Liaison during study
design ensured that methods were closely similar to those used by
Simes and Coates (2001).
For the survival time trade-off, participants considered a
baseline survival of 5 years without adjuvant endocrine therapy,
and were then asked whether they would prefer 5 years survival
without adjuvant endocrine therapy, or a longer survival time with
adjuvant endocrine therapy, with increments ranging from 1 extra
day to 20 extra years. The same process was used for the scenario
with an expected survival time of 15 years except that the
maximum benefit was 30 extra years. For the survival probability
trade-off, participants considered baselines of either a 60% or an
80% 5 year survival rate without adjuvant endocrine therapy, and
were then asked to indicate whether they would prefer the baseline
survival rate without adjuvant endocrine therapy, or a higher
survival rate with adjuvant endocrine therapy, with increments
ranging from 1% to the maximum possible benefit of 20% for the
80% baseline and 40% for the 60% baseline. A sliding ruler was
used to illustrate the trade-offs. The slide was moved back and
forth to show different benefits until the participant identified the
minimum benefit she considered necessary to make adjuvant
endocrine therapy worthwhile.
The effects of changing various aspects of treatment were
tested by giving women hypothetical scenarios based on the
15 year survival time scenario, and then increasing the duration
of therapy from 2 years to 5 years, or omitting the worst side
effect, or changing the route of administration for goserelin from
injection to tablet, or for tamoxifen from tablet to injection.
We also asked women to consider the minimum benefit needed
to make adjuvant endocrine therapy worthwhile if it was for her
sister or best friend.
To address framing effects, the presentation of benefits was
randomised to either start with the smallest benefit and then
increase in magnitude, or start with the largest benefit and then
decrease in magnitude.
Interviews lasted about 30min. All interviewers were trained
at a 2-day course, and/or individually. Explanatory qualitative
data were transcribed from tape (two interviews were not tape
recorded). Taped interviews were checked to provide feedback
to interviewers. Interviewers recorded their perceptions of the
participant’s level of understanding and distress during the
interview.
Data were also collected on the frequency and severity of side
effects attributed to systemic therapy for breast cancer (chemo-
therapy and/or endocrine therapy). Women were asked to
attribute their side effects to a specific treatment. Women also
answered questions about their marital status, employment,
children, and dependants.
Statistical methods
The aims of this study were largely descriptive. The statistical
methods were based on those used in similar previous
studies (Simes and Coates, 2001; Duric et al, 2005). Preference
data were described with graphs of the proportions of women
judging various benefits sufficient to make adjuvant endocrine
therapy worthwhile. The effects of baseline and study factors
used the sum of the two survival time scenarios as the primary
outcome variable to avoid the problems of multiple outcome
measures.
Rater effects were tested by comparing the preferences elicited
by different interviewers using the nonparametric Kruskal–Wallis
test for multiple independent samples. Framing effects were
tested by comparing preferences elicited by starting with the
smallest benefit with those elicited by starting with the largest
benefit using the nonparametric Mann–Whitney test for two
independent samples. Differences in preferences according to
hypothetical variations in treatment duration, side effects, and
delivery were tested with the nonparametric Wilcoxon signed rank
test for paired samples. Differences in preferences according to
whether therapy was intended for the patient or her sister/best
friend were also tested with the Wilcoxon signed rank test for
paired samples.
Associations between preferences and baseline characteristics
were assessed with linear regression models after applying the
normal score transformation to the sum of the two survival time
scenarios. Associations with the following characteristics were
assessed: types of adjuvant systemic therapy (i.e. tamoxifen,
goserelin and chemotherapy), recurrence of cancer, having
children, having a life partner, being employed, age, and time
from randomisation in the clinical trial. The association of each
baseline characteristic with preferences was first tested on its own
(univariable analysis) and then together with other baseline
characteristics (multivariable analysis) (Katz MH, 1999).
SPSS for Windows, version 11.5 was used for all analyses.
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The median age of women was 45 years at the time of interview
(range 31–54). Most were married or living with a partner (84%),
and most had children (88%). Most had tamoxifen, either in
combination with goserelin (50%) or alone (35%); few had
goserelin alone (8%) or no adjuvant endocrine therapy (7%).
Breast cancer had recurred in four out of 85 women. About a third
of the women also had adjuvant chemotherapy (35%).
The most commonly reported endocrine symptoms were hot
flushes (91%), weight gain (80%), sweats (52%) and fatigue (50%).
Women attributed most of their endocrine symptoms to adjuvant
endocrine therapy (range 81–93%). Frequency and severity of side
effects were rated highest by patients who had the combination of
tamoxifen and goserelin (median 19, range 0–83); less with
goserelin alone (median 18, range 2–29); and least for tamoxifen
alone (median 12, range 2–34).
There were no significant effects of interviewers (P¼0.2) or
framing (P¼0.9) on preferences. Interviewers judged that most
women (87%) understood the purpose of the interview and that
most women (84%) had little or no difficulty understanding the
preference questions. Interviewers judged that few women (5%)
were distressed by the interview.
Women’s preferences were highly variable, and while some
judged small benefits sufficient to make adjuvant endocrine
therapy worthwhile, many required much larger benefits as
necessary (see Figures 1 and 2). About a third of women judged
gains of 1% in survival rate or 6 months in survival time sufficient
to make adjuvant endocrine therapy worthwhile. More than half
judged gains of at least 5% or 3 years necessary, and about one in
six judged gains of at least 15% or 10 years necessary to make their
adjuvant endocrine therapy worthwhile.
Changes to various aspects of the hypothetical scenarios
affected women’s preferences. A median gain of 5 years was
judged necessary to make 2 years of adjuvant endocrine therapy
worthwhile on a baseline of 15 years without adjuvant endocrine
therapy. A larger gain was judged necessary if treatment lasted
5 years instead of 2 years (median 7 years, Po0.0001). A smaller
gain was judged sufficient if the worst side effect of adjuvant
endocrine therapy was removed (median 4 years, P¼0.005).
Preferences were not affected by hypothetical changes in the route
of administration (for goserelin: from injection to tablets, P¼0.3;
and, for tamoxifen: from tablet to injection, P¼0.4). There was a
weak trend towards larger gains being judged necessary if the
endocrine therapy was being recommended to a sister or best
friend (median gain of 10 vs 5% on a baseline of 80% 5 year
survival without adjuvant endocrine therapy, P¼0.07).
The effects of baseline characteristics on preferences are
summarised in Table 1. Only two factors were significantly
associated with preferences, and both were significant either alone
in separate models, or together in the same model. Smaller benefits
were judged sufficient by women who had fewer side effects,
and by women who had tamoxifen (either alone or with goserelin).
Preferences for adjuvant endocrine therapy were not associ-
ated with time from trial entry to interview, having adjuvant
chemotherapy, recurrence of breast cancer, or demographic
factors, although there was a weak trend towards employed
women judging smaller benefits sufficient (P¼0.08).
DISCUSSION
A third of the women judged small gains sufficient to make
adjuvant endocrine therapy worthwhile, but over half the women
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Figure 1 Cumulative proportions of women considering whether
adjuvant endocrine therapy would be worthwhile for varying increments
in 5 and 15 year expected survival time (N¼85).
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Figure 2 Cumulative proportions of women considering whether
adjuvant endocrine therapy would be worthwhile for varying increments
in 5 year survival rate of 60 and 80% (N¼85).
Table 1 Factors associated with judging smaller benefits sufficient to
make adjuvant endocrine therapy worthwhile either alone (univariable
analysis) or together (multivariable analysis)
Univariable
analysis P
Multivariable
analysis P
Demographic factors
Age 0.15
Whether she
Was employed at the time of interview 0.08
Has a life partner 0.75
Has any dependant children 0.65
Treatment factors
Less side effects from hormonal treatments 0.02 0.02
Stopped trial treatment early 0.17
Had tamoxifen 0.03 0.04
Had goserelin 0.57
Had adjuvant chemotherapy 0.14
Had a recurrence 0.94
Time elapsed since treatment 0.29
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widespread perception by healthcare professionals that endocrine
therapy has only modest toxicity.
Women who have had adjuvant chemotherapy for early
breast cancer judge small benefits sufficient to make it worth-
while, despite its significant side effects and inconvenience
(Duric and Stockler, 2001; Jansen et al, 2001; Duric et al, 2005).
Adjuvant endocrine therapy provides comparable benefits for
women with hormone-receptor positive disease, and is generally
considered to do so with less severe side effects and less
inconvenience. More than half the women who had adjuvant
endocrine therapy as part of routine clinical practice judged 2%
gain in survival rate or an additional 3–6 months sufficient to
make adjuvant endocrine therapy worthwhile (Thewes et al, 2005).
Yet women in this study required larger benefits to make adjuvant
endocrine worthwhile than those judged necessary to make
chemotherapy worthwhile in comparable studies using almost
identical methods (Duric and Stockler, 2001; Jansen et al, 2001;
Duric et al, 2005) and larger still than those required by women
who had endocrine therapy as part of routine clinical practice
(Thewes et al, 2005).
Our study identified several factors that were associated with the
size of the benefit required to make adjuvant endocrine therapy
worthwhile. Longer duration of therapy and greater toxicity
attributed to therapy were associated with a requirement for
larger improvements. Women who had tamoxifen judged smaller
benefits necessary to make adjuvant endocrine therapy worth-
while, suggesting that tamoxifen was better tolerated than
goserelin. However, the route of administration seemed to matter
less than perceived side effects.
When asked to make similar judgements for their close relative
or best friends, most women judged that greater benefits would be
necessary to make adjuvant endocrine therapy worthwhile for the
other woman.
Despite the similar methods of the two studies, approximately
half the women in the Thewes et al (2005) judged an extra 3
months sufficient compared to women in the current study who
judged an extra 3 years necessary to make adjuvant endocrine
therapy worthwhile. A similar difference occurred on the survival
rate scenarios, with about three-quarters of the women in the
Thewes et al (2005) study judging a 5% improvement sufficient to
justify endocrine therapy, compared to about a third of the women
in our current study. However, about two-thirds of the women in
the Thewes et al (2005) study were treated with tamoxifen alone
compared to about a third of the women in the current study. In
the current study, women who had goserelin alone judged larger
benefits necessary than women who had tamoxifen alone or
goserelin with tamoxifen. This suggests that tamoxifen may reduce
the side effects of goserelin.
All the women in the Thewes et al (2005) study had
chemotherapy as part of routine clinical practice compared
to the current study which was performed within the context
of a clinical trial. Whether trial participation and type of
treatment are factors involved in the apparent differences in
preferences between the two studies needs to be explored in
future research.
Studies of preferences for adjuvant chemotherapy in early breast
cancer found that less severe side effects and having dependents
were associated with smaller benefits being judged sufficient to
make it worthwhile (Duric and Stockler, 2001; Duric et al, 2005).
Severity of side effects was similarly associated with preferences in
this study, but having dependents was not significantly associated
with preferences in this study, perhaps because of the greater
homogeneity of our sample and the small number of women
without dependents. We were surprised not to find an effect of
age. Future studies should explore the importance of fertility
and related issues to younger women considering adjuvant
endocrine therapy.
Our study has limitations. Our sample included women
participating in a randomised trial who may not be representative
of women in general. Our sample included a mixture of
women who had goserelin, tamoxifen, or both. The few women
who did not have endocrine therapy based their judgements
on information about side effects rather than direct experience.
Tamoxifen was given electively to some women and was
randomly allocated to others, so comparisons between women
who did and did not have tamoxifen may be affected by selection
bias. About a third of the women had chemotherapy also and
distinguishing between the side effects of the various treatments
would have been difficult. This kind of research has other
limitations that have been discussed in detail previously (Duric
et al, 2005). Preferences were based on women’s recollections of
what treatment was like, and were likely to be influenced by
psychological mechanisms, including memory, adaptation, coping,
and cognitive dissonance reduction. Furthermore, because only
women who had adjuvant endocrine therapy were recruited, they
are not representative of all women considering whether to have
adjuvant endocrine therapy.
Endocrine therapy and chemotherapy are very different
treatments. The side effects of endocrine therapy are
generally considered milder but are longer lasting than those of
chemotherapy. The finding that women having adjuvant
endocrine therapy judged larger benefits necessary to make it
worthwhile than women having adjuvant chemotherapy is
striking. It suggests that shorter treatments are easier to cope
with even if they have more severe side effects. However,
comparisons of our results with those from studies of
women having adjuvant chemotherapy should be interpreted
cautiously because, although the methods were very similar,
they were not identical and the populations were different. Women
in our study were younger, and about a third had already had
chemotherapy.
Studies of preferences offer valuable information to clinicians,
patients, and communities about the benefits patients require to
make treatments worthwhile. The benefits required to make
adjuvant endocrine therapy worthwhile were larger than we
expected suggesting that the side effects of adjuvant endocrine
therapy were more important to women than we expected.
Clinicians should ask women about their circumstances, priorities,
and concerns because these may influence their choices
about treatment. Research is also needed to determine the best
way to elicit and incorporate this kind of information in clinical
decision-making.
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